Trump Nominates Anti-Vaccine Expert Kennedy to Lead HHS
On November 14, 2024, President Donald Trump officially announced his intention to nominate Robert F. Kennedy Jr. to serve as Secretary of the Department of Health and Human Services (HHS) in his new administration. This decision has aroused widespread public concern and controversy.
Since 2005, Kennedy has continued to argue for a link between vaccines and autism, although this view has been widely rejected by the scientific community. He has also argued that the COVID-19 virus is "racially directed," primarily affecting whites and blacks, while Ashkenazi Jews and Chinese are less affected.
In announcing his nomination, Trump emphasized Kennedy's commitment to reforming the U.S. health care system to ensure the public is protected from harmful chemicals, pollutants, pesticides, drugs and food additives. He also said Kennedy would work to restore HHS's tradition of scientific research and increase transparency to address the nation's chronic disease epidemic.
If Trump's nomination is confirmed by the Senate, Kennedy would be responsible for leading HHS, which has a budget of $1.7 trillion, and overseeing key agencies including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Centers for Medicare and Medicaid Services (CMS). Kennedy had previously revealed plans to lay off 600 NIH employees on his first day in office, signaling a potential major change for the agency.
The nomination has been widely discussed in medical and political circles. Many public health experts have expressed concern about Kennedy's anti-vaccine stance, arguing that it could have implications for current vaccination policies and public health strategies in the United States. At the same time, some members of the Republican Party are also wary of the nomination, fearing that it may cause unnecessary controversy.
The Senate has yet to vote on the nomination, and it remains to be seen whether Kennedy will succeed.
2026-10-22
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
South Korea Approves Yeosu Restructuring Plan, Permanently Retiring 1.39 Million Tons of Ethylene Capacity
-
Sika in China Under Pressure: The Structural Alarm Behind the 1,500-Job Cut
-
Blue from the Rainforest: EFSA Greenlights Natural “Jagua Blue” as Safe Food Colorant
-
From Eggshell to Elixir: EFSA Declares Egg Membrane Collagen Peptides Safe for Adult Supplements
-
Probiotic Promise, Safety Snag: EFSA Gives Mixed Verdict on Multi-Strain Dog Feed Additive
-
From Ancient Volcanoes to Modern Feed Mills: EFSA Validates Volcanic Zeolite as Safe and Effective Feed Additive
-
Spice Up the Coop: EFSA Reaffirms Safety of Botanical Blend for Broiler Feed—With a Warning for Handlers
-
New Ocean Freight GRI Takes Effect on Asia, Middle East and Africa Routes to U.S. and Canada
-
Sun-Kissed Insect Oil? EFSA Approves UV-Treated Mealworm Fat as Safe—and Vitamin D-Rich—Novel Food
-
From Fungus to Food: EFSA Greenlights Rhizomucor pusillus Biomass as Safe Novel Ingredient
Recommend Reading
-
Behind Arkema’s ¥430 Million Claim: A Patent War Over Acrylic Acid Is Tearing Off the “Technical Fig Leaf” of China’s Chemical Giants
-
Libya’s Largest Refinery Faces Full Shutdown After Five Rounds of Airstrikes
-
SIBUR’s Massive Siberian Petrochemical Complex Shuts After Drone Attack, LPG Supply Disrupted
-
French Cosmetics Exports Poised for First Drop in Over Two Decades in 2025
-
Europe Faces 510,000-BPD Q4 Jet Fuel Deficit as ARA Stocks Hit Seven-Year Low
-
Premium Global Chemical Sourcing Requests (23 - 27 Feb, 2026)
-
Bullish Support Pushes Up January Adipic Acid Prices in China
-
Production and Sales Pressure Eases; PC Prices Rise from Low Levels in Mid-January
-
Key Events in the Epoxy Resins Industry in February 2026
-
Expectations of Tightening Supply Dominate the Recovery in Formic Acid Prices